Plus Therapeutics to Present Data from ReSPECT-GBM Clinical Trial at the European Society for Medical Oncology Congress 2022 (GlobeNewswire) - Aug 23, 2022 - "Plus Therapeutics, Inc...announced it will present data from the Phase 1/2a ReSPECT-GBM™ dose escalation clinical trial evaluating the Company's lead investigational targeted radiotherapeutic, Rhenium-186 NanoLiposome (186RNL), in recurrent glioblastoma in an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2022, being held September 9-13, 2022 in Paris, France."
P1/2 data • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor
|